Profile
Thomas Tscherning is currently the Chairman at Frigoscandia AB. He was previously the Chairman at Zymenex A, Director at Nereus Pharmaceuticals, Inc., Director at AGC Biologics A, Director at Cellectis SA, Non-Executive Director at F2G Ltd., Director at Halda AB, Director at Warren Pharmaceuticals, Inc., Director at Inzile AB, and Manager & Partner at BI Technology A. He graduated from Karolinska Institutet and received a doctorate degree from the University of Copenhagen in 1995.
Thomas Tscherning active positions
| Companies | Position | Start |
|---|---|---|
Frigoscandia AB
Frigoscandia AB Air Freight/CouriersTransportation Provides temperature-controlled logistics and warehousing services | Chairman | - |
Former positions of Thomas Tscherning
| Companies | Position | End |
|---|---|---|
| INZILE AB (PUBL) | Director/Board Member | 23/08/2021 |
Halda AB
Halda AB Electronics DistributorsDistribution Services Provides traffic management and payment administration services | Director/Board Member | 07/10/2011 |
BI Technology A/S
BI Technology A/S Investment ManagersFinance BI-T is an active venture capital investment manager following a hands-on approach and investing primarily in high-growth life science technology companies with global expansion potential. Investment criteria include an experienced management team, an innovative business concept with a competitive edge based on proven distinctive technology, a clearly defined medical need and patient population, and adequate IP protection by a strong patent portfolio. The firm focuses on unlisted, research-based biotechnology companies dedicated to developing profitable pharmaceuticals for the treatment of human diseases. They pay attention to unmet medical needs, potential medical improvements and major markets. They favor companies with advanced R&D supporting a market launch in the foreseeable future. They invest primarily in Europe, particularly in Denmark and the Nordic countries, and occasionally in the US where they co-invest with third parties. BI-T also invests in the energy technology field, focusing on renewable energy, energy storage, conversion and distribution as well as on improvements to the traditional energy sector. They aim to support the profitable development of sustainable and environmentally-clean alternative energies such as wind, water and solar power as well as clean fuels such as natural gas, hydrogen and biofuels. They invest in Denmark and Europe through direct equity participations in share increases, and target companies with attractive exit potential. They favor startups and early-expansion-stage companies with a credible business model based on proprietary products or services. BI-T provides intensive advisory and consultancy services to their portfolio companies. They follow up their initial investment with additional capital. The firm exits their investments through IPOs and trade sales, and their targeted exit horizon is three to ten years. Finally, the firm is involved in private equity investing in emerging markets in Africa and Asia, particularly in Vietnam, South Africa, East Africa and Egypt. Their investments are often supported by DANIDA-Danish International Development Assistance grants. Investments in Southeast Asia are managed out of a representative office in Ho Chi Minh City, Vietnam. | Private Equity Investor | 01/01/2010 |
| ZEALAND PHARMA A/S | Director/Board Member | 01/01/2010 |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology Engages in research and development of novel drugs for life-threatening systemic fungal diseases treatment | Director/Board Member | - |
Training of Thomas Tscherning
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 13 |
|---|---|
Karolinska Institutet
Karolinska Institutet Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Nereus Pharmaceuticals, Inc.
Nereus Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Discovers and develops therapeutics for cancer, inflammatory, and infectious diseases | Commercial Services |
BI Technology A/S
BI Technology A/S Investment ManagersFinance BI-T is an active venture capital investment manager following a hands-on approach and investing primarily in high-growth life science technology companies with global expansion potential. Investment criteria include an experienced management team, an innovative business concept with a competitive edge based on proven distinctive technology, a clearly defined medical need and patient population, and adequate IP protection by a strong patent portfolio. The firm focuses on unlisted, research-based biotechnology companies dedicated to developing profitable pharmaceuticals for the treatment of human diseases. They pay attention to unmet medical needs, potential medical improvements and major markets. They favor companies with advanced R&D supporting a market launch in the foreseeable future. They invest primarily in Europe, particularly in Denmark and the Nordic countries, and occasionally in the US where they co-invest with third parties. BI-T also invests in the energy technology field, focusing on renewable energy, energy storage, conversion and distribution as well as on improvements to the traditional energy sector. They aim to support the profitable development of sustainable and environmentally-clean alternative energies such as wind, water and solar power as well as clean fuels such as natural gas, hydrogen and biofuels. They invest in Denmark and Europe through direct equity participations in share increases, and target companies with attractive exit potential. They favor startups and early-expansion-stage companies with a credible business model based on proprietary products or services. BI-T provides intensive advisory and consultancy services to their portfolio companies. They follow up their initial investment with additional capital. The firm exits their investments through IPOs and trade sales, and their targeted exit horizon is three to ten years. Finally, the firm is involved in private equity investing in emerging markets in Africa and Asia, particularly in Vietnam, South Africa, East Africa and Egypt. Their investments are often supported by DANIDA-Danish International Development Assistance grants. Investments in Southeast Asia are managed out of a representative office in Ho Chi Minh City, Vietnam. | Finance |
Zymenex A/S
Zymenex A/S BiotechnologyHealth Technology Engages in the research and development of therapeutics for life threatening diseases | Health Technology |
Zealand Pharma A/S
Zealand Pharma A/S BiotechnologyHealth Technology Operates as a biotechnology company that discovers and develops peptide based medicines | Health Technology |
AGC Biologics A/S
AGC Biologics A/S Pharmaceuticals: MajorHealth Technology Operates as a global contract process development and manufacturer of biopharmaceuticals | Health Technology |
Cellectis SA
Cellectis SA Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops immunotherapies | Health Technology |
University of Copenhagen
University of Copenhagen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology Engages in research and development of novel drugs for life-threatening systemic fungal diseases treatment | Health Technology |
Halda AB
Halda AB Electronics DistributorsDistribution Services Provides traffic management and payment administration services | Distribution Services |
Warren Pharmaceuticals, Inc.
Warren Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops tissue-protective technologies | Health Technology |
Frigoscandia AB
Frigoscandia AB Air Freight/CouriersTransportation Provides temperature-controlled logistics and warehousing services | Transportation |
Inzile AB
Inzile AB Motor VehiclesConsumer Durables Manufactures and sells electric vehicles for local transportation | Consumer Durables |
- Stock Market
- Insiders
- Thomas Tscherning
















